Jerad G. Seurer, General Counsel and Corporate Secretary of InMed Pharmaceuticals Inc. (now operating as Mentari Therapeutics, Inc.), filed an initial statement of beneficial ownership on November 12, 2026, reporting a stock option position received in connection with a corporate merger effective November 6, 2026.

Key Highlights

  • Reporting person: Jerad G. Seurer, General Counsel and Corporate Secretary, filed an initial beneficial ownership statement with an event date of November 6, 2026.
  • Stock option disclosed: Seurer holds a stock option (right to buy) covering 93,411 shares of common stock at an exercise price of $10.37, expiring September 24, 2036, held directly.
  • Option origin: According to the filing, the option was received in exchange for options of Pre-Merger Mentari held by Seurer prior to the merger.
  • Vesting schedule: The option vests as to 25% on August 3, 2027, then in equal monthly installments through August 3, 2030, subject to continued service.
  • Merger structure: The filing describes a two-step merger effective November 6, 2026, in which Indigo Merger Sub Corp. merged with Pre-Merger Mentari, followed by a second merger into Indigo Merger Sub II, LLC, surviving as Mentari Therapeutics Operating Company LLC.
  • No non-derivative securities reported: Table I of the filing lists no directly or indirectly owned non-derivative securities.

Seurer's Initial Ownership Disclosure Following the Mentari-InMed Merger

InMed Pharmaceuticals Inc., listed on NASDAQ:MTRI and described in the filing as formerly known as InMed Pharmaceuticals Inc. and now operating under the Mentari Therapeutics name, is the issuer identified in this Form 3. The filing was submitted by Jerad G. Seurer, identified as the company's General Counsel and Corporate Secretary, whose address is listed as 221 Crescent St., Building 23, Suite 105, Waltham, Massachusetts 02453.

The event triggering the initial statement was November 6, 2026, the effective date of a two-step merger transaction. According to the filing, Indigo Merger Sub Corp., a wholly owned subsidiary of the issuer, first merged with Pre-Merger Mentari Therapeutics, Inc. (a Delaware corporation), with Pre-Merger Mentari continuing as a wholly owned subsidiary and the surviving entity. Immediately thereafter, Pre-Merger Mentari merged into Indigo Merger Sub II, LLC, a second wholly owned subsidiary, which survived under the name Mentari Therapeutics Operating Company LLC.

As a result of that merger, Seurer received a stock option to purchase 93,411 shares of the issuer's common stock at $10.37 per share, expiring September 24, 2036, in exchange for options he had held in Pre-Merger Mentari. The filing states the option is held directly and will vest as to 25% on August 3, 2027, with the remainder vesting in equal monthly installments through August 3, 2030, contingent on Seurer's continued service to the issuer on each vesting date. No non-derivative securities were reported in Table I of the filing.

What Was Disclosed

Jerad G. Seurer filed a Form 3 initial beneficial ownership statement disclosing one stock option covering 93,411 shares at $10.37, obtained through a November 6, 2026 merger between InMed Pharmaceuticals Inc. and Mentari Therapeutics entities, with vesting running from 2027 through 2030.